{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:56:16Z","timestamp":1790056576759,"version":"4.0.1"},"reference-count":51,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0006_s_001_w2aab3b7b1b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d5917655e360_w2aab3b7b1b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>The randomized trial PRODIGE 7 failed to show the benefit of oxaliplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal peritoneal metastasis treatment (CR PM). This systematic review focuses on the association of cisplatin (CDDP) with mitomycin C (MMC) in HIPEC in CR PM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0006_s_002_w2aab3b7b1b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d5917655e368_w2aab3b7b1b1b6b1aab1c16b2aAa\">Content<\/jats:title>\n                    <jats:p>\n                      Experimental studies demonstrated that hyperthermia, in addition to CDDP\u2009\u00b1\u2009MMC treatment, gradually improved the cytotoxic effect by increasing early apoptosis, eATP interaction, intracellular CDDP concentration (by 20%) and p73 expression. Recent studies with highly selected patients reported unusual prolonged survival with a median overall survival (OS) of approximately 60 months, with a HIPEC combination of CDDP (25 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/L) plus MMC (3.3 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/L) at a temperature of 41.5\u201342.5\u2006\u00b0C for 60\u201390 min. Major complications occurred in less than 30% of patients with limited hematological toxicity (less than 15%). In addition, in a phase 2 trial, an adjuvant HIPEC benefit was demonstrated in colorectal cancer patients with high risk for peritoneal failure (5-year OS: 81.3% vs. 70% for the HIPEC group vs. the control group, respectively, p=0.047). After a recurrence, an iterative procedure permitted similar recurrence-free disease (13 vs. 13.7 months) with an acceptable morbidity (18.7% of severe complications).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0006_s_003_w2aab3b7b1b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d5917655e382_w2aab3b7b1b1b6b1aab1c16b3aAa\">Summary and outlook<\/jats:title>\n                    <jats:p>The combination of CDDP and MMC seems to be an interesting protocol as an alternative to high-dose and short-term oxaliplatin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0006","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T05:03:45Z","timestamp":1559106225000},"source":"Crossref","is-referenced-by-count":23,"title":["Hyperthermic intraperitoneal chemotherapy with cisplatin and mitomycin C for colorectal cancer peritoneal metastases: A systematic review of the literature"],"prefix":"10.1515","volume":"4","author":[{"given":"Amandine","family":"Pinto","sequence":"first","affiliation":[{"name":"Inserm U1275 - Carcinose P\u00e9ritoine et Paris-Technologie , INSERM , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[{"name":"U1275 - Carcinose P\u00e9ritoine et Paris-Technologie , INSERM , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"2025120909240997645_j_pp-2019-0006_ref_001_w2aab3b7b1b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212\u201322.10.1097\/01.sla.0000197702.46394.1616432354","DOI":"10.1097\/01.sla.0000197702.46394.16"},{"key":"2025120909240997645_j_pp-2019-0006_ref_002_w2aab3b7b1b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"Klaver YL, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options. World J Gastroenterol. 2012;18:5489\u201394.10.3748\/wjg.v18.i39.548923112540","DOI":"10.3748\/wjg.v18.i39.5489"},{"key":"2025120909240997645_j_pp-2019-0006_ref_003_w2aab3b7b1b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"Klaver CE, Musters GD, Bemelman WA, Punt CJ, Verwaal VJ, Dijkgraaf MG, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at righ risk of peritoneal carcinomatosis; the COLOPEC randomizerd muticentre trial. BMC Cancer. 2015;15:428.10.1186\/s12885-015-1430-7","DOI":"10.1186\/s12885-015-1430-7"},{"key":"2025120909240997645_j_pp-2019-0006_ref_004_w2aab3b7b1b1b6b1ab1b5b4Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63\u20138.1991786310.1200\/JCO.2009.23.9285","DOI":"10.1200\/JCO.2009.23.9285"},{"key":"2025120909240997645_j_pp-2019-0006_ref_005_w2aab3b7b1b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681\u20135.1910372810.1200\/JCO.2008.19.7160","DOI":"10.1200\/JCO.2008.19.7160"},{"key":"2025120909240997645_j_pp-2019-0006_ref_006_w2aab3b7b1b1b6b1ab1b5b6Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach ? Lancet Oncol. 2012;13:362\u20139.10.1016\/S1470-2045(12)70210-3","DOI":"10.1016\/S1470-2045(12)70210-3"},{"key":"2025120909240997645_j_pp-2019-0006_ref_007_w2aab3b7b1b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2:109\u201316.10.4251\/wjgo.v2.i2.10921160929","DOI":"10.4251\/wjgo.v2.i2.109"},{"key":"2025120909240997645_j_pp-2019-0006_ref_008_w2aab3b7b1b1b6b1ab1b5b8Aa","doi-asserted-by":"crossref","unstructured":"Chua TC, Yan TD, Zhao J, Morris DL. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. Eur J Surg Oncol. 2009;35:1299\u2013305.10.1016\/j.ejso.2009.07.00519632081","DOI":"10.1016\/j.ejso.2009.07.005"},{"key":"2025120909240997645_j_pp-2019-0006_ref_009_w2aab3b7b1b1b6b1ab1b5b9Aa","doi-asserted-by":"crossref","unstructured":"Quenet F, Go\u00e9r\u00e9 D, Mehta SS, Roca L, Dumont F, Hessissen M, et al. Results of two Bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294\u2013301.10.1097\/SLA.0b013e318226393321772129","DOI":"10.1097\/SLA.0b013e3182263933"},{"key":"2025120909240997645_j_pp-2019-0006_ref_010_w2aab3b7b1b1b6b1ab1b5c10Aa","doi-asserted-by":"crossref","unstructured":"Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? 2018. Eur J Surg Oncol. 2019;45:400\u20132.10.1016\/j.ejso.2018.10.54230392745","DOI":"10.1016\/j.ejso.2018.10.542"},{"key":"2025120909240997645_j_pp-2019-0006_ref_011_w2aab3b7b1b1b6b1ab1b5c11Aa","doi-asserted-by":"crossref","unstructured":"Van der Speeten K, Lemoine L, Sugarbaker P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum. 2017;2:63\u201372.30911634","DOI":"10.1515\/pp-2017-0003"},{"key":"2025120909240997645_j_pp-2019-0006_ref_012_w2aab3b7b1b1b6b1ab1b5c12Aa","doi-asserted-by":"crossref","unstructured":"Eveno C, Pocard M. Randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review. Pleura Peritoneum. 2016;1:169\u201382.30911621","DOI":"10.1515\/pp-2016-0027"},{"key":"2025120909240997645_j_pp-2019-0006_ref_013_w2aab3b7b1b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Reymond MA. The quest of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): searching for evidence. Pleura Peritoneum. 2016;1:167\u20138.30911620","DOI":"10.1515\/pp-2016-0026"},{"key":"2025120909240997645_j_pp-2019-0006_ref_014_w2aab3b7b1b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, et al. Human pharmacokinetic study oh heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology. 2002;63:346\u201352.10.1159\/000066229","DOI":"10.1159\/000066229"},{"key":"2025120909240997645_j_pp-2019-0006_ref_015_w2aab3b7b1b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Pocard M, Sideris L, Ed\u00e8 C, Ducreux M, Boige V, et al. Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004;91:455\u20136.10.1002\/bjs.439915048746","DOI":"10.1002\/bjs.4399"},{"key":"2025120909240997645_j_pp-2019-0006_ref_016_w2aab3b7b1b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116:5608\u201318.10.1002\/cncr.2535620737573","DOI":"10.1002\/cncr.25356"},{"key":"2025120909240997645_j_pp-2019-0006_ref_017_w2aab3b7b1b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Hompes D, D\u2019Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, et al. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109:527\u201332.10.1002\/jso.2354624375059","DOI":"10.1002\/jso.23546"},{"key":"2025120909240997645_j_pp-2019-0006_ref_018_w2aab3b7b1b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Van Eden WJ, Kok NF, Woensdregt K, Huitema AD, Boot H, Aalbers AGJ. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44:220\u20137.10.1016\/j.ejso.2017.10.21629258720","DOI":"10.1016\/j.ejso.2017.10.216"},{"key":"2025120909240997645_j_pp-2019-0006_ref_019_w2aab3b7b1b1b6b1ab1b5c19Aa","doi-asserted-by":"crossref","unstructured":"Prada-Villaverde A, Esquivel J. The American Society of peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;21:2608\u201314.","DOI":"10.1002\/jso.23728"},{"key":"2025120909240997645_j_pp-2019-0006_ref_020_w2aab3b7b1b1b6b1ab1b5c20Aa","doi-asserted-by":"crossref","unstructured":"Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Quenet F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315\u201322.2692038510.1245\/s10434-016-5143-1","DOI":"10.1245\/s10434-016-5143-1"},{"key":"2025120909240997645_j_pp-2019-0006_ref_021_w2aab3b7b1b1b6b1ab1b5c21Aa","doi-asserted-by":"crossref","unstructured":"Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36:1.","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503"},{"key":"2025120909240997645_j_pp-2019-0006_ref_022_w2aab3b7b1b1b6b1ab1b5c22Aa","doi-asserted-by":"crossref","unstructured":"Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.2934239310.1056\/NEJMoa1708618","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909240997645_j_pp-2019-0006_ref_023_w2aab3b7b1b1b6b1ab1b5c23Aa","doi-asserted-by":"crossref","unstructured":"Baratti D, Kusamura S, Iusco D, Gimondi S, Pietrantonio F, Milione M, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases. Ann Surg Oncol. 2017;24:167\u201375.10.1245\/s10434-016-5488-527519353","DOI":"10.1245\/s10434-016-5488-5"},{"key":"2025120909240997645_j_pp-2019-0006_ref_024_w2aab3b7b1b1b6b1ab1b5c24Aa","doi-asserted-by":"crossref","unstructured":"Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, et al. Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018;61:1026\u201334.10.1097\/DCR.000000000000115630086051","DOI":"10.1097\/DCR.0000000000001156"},{"key":"2025120909240997645_j_pp-2019-0006_ref_025_w2aab3b7b1b1b6b1ab1b5c25Aa","doi-asserted-by":"crossref","unstructured":"Baratti D, Kusamura S, Iusco D, Bonomi S, Grassi A, Virz\u00ec S, et al. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum. 2014;57:858\u201368.10.1097\/DCR.000000000000014924901687","DOI":"10.1097\/DCR.0000000000000149"},{"key":"2025120909240997645_j_pp-2019-0006_ref_026_w2aab3b7b1b1b6b1ab1b5c26Aa","doi-asserted-by":"crossref","unstructured":"Huang CQ, Yang XJ, Yu Y, Wu HT, Liu Y, Yonemura Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center. PLoS One. 2014;9:e108509.10.1371\/journal.pone.010850925259574","DOI":"10.1371\/journal.pone.0108509"},{"key":"2025120909240997645_j_pp-2019-0006_ref_027_w2aab3b7b1b1b6b1ab1b5c27Aa","doi-asserted-by":"crossref","unstructured":"Lin EK, Hsieh MC, Chen CH, Lu YJ, Wu SY. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. Medicine. 2016;95:e5522.2803324710.1097\/MD.0000000000005522","DOI":"10.1097\/MD.0000000000005522"},{"key":"2025120909240997645_j_pp-2019-0006_ref_028_w2aab3b7b1b1b6b1ab1b5c28Aa","doi-asserted-by":"crossref","unstructured":"Cesna V, Sukovas A, Jasukaitiene A, Naginiene R, Barauskas G, Dambrauskas Z, et al. Narrow line between benefit and harm: additivity of hyperthermia to cisplatin cytotoxicity in different gastrointestinal cancer cells. World J Gastroenterol. 2018;24:1072\u201383.2956375210.3748\/wjg.v24.i10.1072","DOI":"10.3748\/wjg.v24.i10.1072"},{"key":"2025120909240997645_j_pp-2019-0006_ref_029_w2aab3b7b1b1b6b1ab1b5c29Aa","doi-asserted-by":"crossref","unstructured":"Ried M, Potzger T, Braune N, Diez C, Neu R, Sziklavari Z, et al. Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies. J Surg Oncol. 2013;107:735\u201340.10.1002\/jso.2332123386426","DOI":"10.1002\/jso.23321"},{"key":"2025120909240997645_j_pp-2019-0006_ref_030_w2aab3b7b1b1b6b1ab1b5c30Aa","doi-asserted-by":"crossref","unstructured":"Tang R, Zhu ZG, Qu Y, Li JF, Ji YB, Cai Q, et al. The impact of hyperthermic chemotherapy on human gastric cancer cell lines: preliminary results. Oncol Rep. 2006;16:631\u201341.16865266","DOI":"10.3892\/or.16.3.631"},{"key":"2025120909240997645_j_pp-2019-0006_ref_031_w2aab3b7b1b1b6b1ab1b5c31Aa","doi-asserted-by":"crossref","unstructured":"Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One. 2008;3:e2599.1861241510.1371\/journal.pone.0002599","DOI":"10.1371\/journal.pone.0002599"},{"key":"2025120909240997645_j_pp-2019-0006_ref_032_w2aab3b7b1b1b6b1ab1b5c32Aa","doi-asserted-by":"crossref","unstructured":"De Andrade Mello P, Bian S, Savio LE, Zhang H, Zhang J, Junger W, et al. Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death. Oncotarget. 2017;8:67254\u201368.28978031","DOI":"10.18632\/oncotarget.18595"},{"key":"2025120909240997645_j_pp-2019-0006_ref_033_w2aab3b7b1b1b6b1ab1b5c33Aa","doi-asserted-by":"crossref","unstructured":"Sottile ML, Losinno AD, Fanelli MA, Cuello-Carri\u00f3n FD, Montt-Guevara MM, Vargas-Roig LM, et al. Hyperthermia effects on Hsp27 and Hsp72 associations with mismatch repair (MMR) proteins and cisplatin toxicity in MMR-deficient\/proficient colon cancer cell lines. Int J Hyperthermia. 2015;31:464\u201375.10.3109\/02656736.2015.102684826043026","DOI":"10.3109\/02656736.2015.1026848"},{"key":"2025120909240997645_j_pp-2019-0006_ref_034_w2aab3b7b1b1b6b1ab1b5c34Aa","doi-asserted-by":"crossref","unstructured":"Bhagwandin S, Naffouje S, Salti G. Utility of chemoresponse assay in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22:2573\u20137.2557268010.1245\/s10434-014-4330-1","DOI":"10.1245\/s10434-014-4330-1"},{"key":"2025120909240997645_j_pp-2019-0006_ref_035_w2aab3b7b1b1b6b1ab1b5c35Aa","doi-asserted-by":"crossref","unstructured":"Makrin V, Lev-Chelouche D, Even Sapir E, Paran H, Rabau M, Gutman M. Intraperitoneal heated chemotherapy affects healing of experimental colonic anastomosis: an animal study. J Surg Oncol. 2005;89:18\u201322.10.1002\/jso.2016115612012","DOI":"10.1002\/jso.20161"},{"key":"2025120909240997645_j_pp-2019-0006_ref_036_w2aab3b7b1b1b6b1ab1b5c36Aa","doi-asserted-by":"crossref","unstructured":"Aghayeva A, Benlice C, Bilgin IA, Atukeren P, Dogusoy G, Demir F, et al. The effects of hyperthermic intraperitoneal chemoperfusion on colonic anastomosis: an experimental study in a rat model. Tumori. 2017;103:307\u201313.10.5301\/tj.5000610","DOI":"10.5301\/tj.5000610"},{"key":"2025120909240997645_j_pp-2019-0006_ref_037_w2aab3b7b1b1b6b1ab1b5c37Aa","doi-asserted-by":"crossref","unstructured":"Bevanda M, Orsolic N, Basic I, Vukojevic K, Benkovic V, Horvat Knezevic A, et al. Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2. Int J Hyperthermia. 2009;25:132\u201340.10.1080\/0265673080252069719337913","DOI":"10.1080\/02656730802520697"},{"key":"2025120909240997645_j_pp-2019-0006_ref_038_w2aab3b7b1b1b6b1ab1b5c38Aa","doi-asserted-by":"crossref","unstructured":"Yun Q, Wang SS, Xu S, Yang JP, Fan J, Yang LL, et al. Use of 5-fluorouracil loaded micelles and cisplatin in thermosensitive chitosan hydrogel as an efficient therapy against colorectal peritoneal carcinomatosis. Macromol Biosci. 2017;17.27762505","DOI":"10.1002\/mabi.201600262"},{"key":"2025120909240997645_j_pp-2019-0006_ref_039_w2aab3b7b1b1b6b1ab1b5c39Aa","doi-asserted-by":"crossref","unstructured":"Cavaliere F, Di Filippo F, Botti C, Cosimelli M, Giannarelli D, Aloe L, et al. Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. Eur J Surg Oncol. 2000;26:486\u201391.1101647110.1053\/ejso.1999.0927","DOI":"10.1053\/ejso.1999.0927"},{"key":"2025120909240997645_j_pp-2019-0006_ref_040_w2aab3b7b1b1b6b1ab1b5c40Aa","doi-asserted-by":"crossref","unstructured":"Cavaliere F, Perri P, Di Filippo F, Giannarelli D, Botti C, Cosimelli M, et al. Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol. 2000;74:41\u20134.10.1002\/1096-9098(200005)74:1<41::AID-JSO10>3.0.CO;2-R10861608","DOI":"10.1002\/1096-9098(200005)74:1<41::AID-JSO10>3.0.CO;2-R"},{"key":"2025120909240997645_j_pp-2019-0006_ref_041_w2aab3b7b1b1b6b1ab1b5c41Aa","doi-asserted-by":"crossref","unstructured":"Cavaliere F, De Simone M, Virz\u00ec S, Deraco M, Rossi CR, Garofalo A, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37:148\u201354.10.1016\/j.ejso.2010.10.01421093205","DOI":"10.1016\/j.ejso.2010.10.014"},{"key":"2025120909240997645_j_pp-2019-0006_ref_042_w2aab3b7b1b1b6b1ab1b5c42Aa","doi-asserted-by":"crossref","unstructured":"Pilati P, Mocellin S, Rossi CR, Foletto M, Campana L, Nitti D, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol. 2003;10:508\u201313.10.1245\/ASO.2003.08.00412794016","DOI":"10.1245\/ASO.2003.08.004"},{"key":"2025120909240997645_j_pp-2019-0006_ref_043_w2aab3b7b1b1b6b1ab1b5c43Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J. 2013;2013:978394.","DOI":"10.1155\/2013\/978394"},{"key":"2025120909240997645_j_pp-2019-0006_ref_044_w2aab3b7b1b1b6b1ab1b5c44Aa","unstructured":"Vaira M, Cioppa T, D\u2019Amico S, de Marco G, D\u2019Alessandro M, Fiorentini G, et al. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years. In Vivo. 2010;24:79\u201384.20133981"},{"key":"2025120909240997645_j_pp-2019-0006_ref_045_w2aab3b7b1b1b6b1ab1b5c45Aa","doi-asserted-by":"crossref","unstructured":"Chalret du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, et al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol. 2014;74:571\u201382.25053386","DOI":"10.1007\/s00280-014-2525-6"},{"key":"2025120909240997645_j_pp-2019-0006_ref_046_w2aab3b7b1b1b6b1ab1b5c46Aa","doi-asserted-by":"crossref","unstructured":"Virz\u00ec S, Iusco D, Baratti D, Bonomi S, Grassi A, Kusamura S, et al. Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. Tumori. 2013;99:589\u201395.2436286210.1177\/030089161309900505","DOI":"10.1177\/030089161309900505"},{"key":"2025120909240997645_j_pp-2019-0006_ref_047_w2aab3b7b1b1b6b1ab1b5c47Aa","doi-asserted-by":"crossref","unstructured":"Vaira M, Robella M, Mellano A, Sottile A, De Simone M. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int J Hyperthermia. 2014;30:565\u20139.2543098810.3109\/02656736.2014.974693","DOI":"10.3109\/02656736.2014.974693"},{"key":"2025120909240997645_j_pp-2019-0006_ref_048_w2aab3b7b1b1b6b1ab1b5c48Aa","doi-asserted-by":"crossref","unstructured":"K\u00f6nigsrainer A, Rau B. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) : don\u2019t throw the baby out with the bathwater. Pleura Peritoneum. 2018;3:20180131.30911670","DOI":"10.1515\/pp-2018-0131"},{"key":"2025120909240997645_j_pp-2019-0006_ref_049_w2aab3b7b1b1b6b1ab1b5c49Aa","doi-asserted-by":"crossref","unstructured":"De Jong LA, Elekonawo FM, de Reuver PR, Bremers AJ, de Wilt JH, Jansman FG, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. Br J Clin Pharmacol. 2019;85:47\u201358.10.1111\/bcp.1377330255585","DOI":"10.1111\/bcp.13773"},{"key":"2025120909240997645_j_pp-2019-0006_ref_050_w2aab3b7b1b1b6b1ab1b5c50Aa","doi-asserted-by":"crossref","unstructured":"Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:144\u20139.2778067510.1016\/j.ejso.2016.09.015","DOI":"10.1016\/j.ejso.2016.09.015"},{"key":"2025120909240997645_j_pp-2019-0006_ref_051_w2aab3b7b1b1b6b1ab1b5c51Aa","doi-asserted-by":"crossref","unstructured":"Pinto A, Pocard M. Photodynamic therapy and photothermal therapy for the treatment of peritoneal metastasis: a systematic review. Pleura Peritoneum. 2018;3:20180124.30911668","DOI":"10.1515\/pp-2018-0124"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/2\/article-20190006.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0006\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0006\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:02:09Z","timestamp":1765278129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0006\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6,28]]},"published-print":{"date-parts":[[2019,6,26]]}},"alternative-id":["10.1515\/pp-2019-0006"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0006","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"article-number":"20190006"}}